Table 2

Annualised risks and HRs of primary and secondary outcomes

OutcomesPotent P2Y12 inhibitor
(95% CI)		Clopidogrel
(95% CI)		Hazard ratio (95% CI)P value
Primary efficacy  
 Ischaemic stroke1.15%
(0.83% to 1.61%)		2.02%
(1.57% to 2.59%)		0.57
(0.37 to 0.87)		0.008
Secondary efficacy   
 Composite of all-cause mortality, myocardial infarction and ischaemic stroke9.30%
(8.26% to 10.47%)		12.12%
(10.91% to 13.47%)		0.77
(0.66 to 0.90)		0.001
 All-cause mortality3.24%
(2.66% to 3.95%)		2.78%
(2.24% to 3.43%)		1.17
(0.87 to 1.56)		0.30
 Myocardial infarction5.99%
(5.17% to 6.94%)		8.42%
(7.43% to 9.55%)		0.71
(0.59 to 0.87)		0.001
Primary safety  
 Intracranial haemorrhage0.49%
(0.30% to 0.82%)		0.75%
(0.50% to 1.13%)		0.65
(0.34 to 1.25)		0.20
Secondary safety   
 Major bleeding6.04%
(5.22% to 7.00%)		7.27%
(6.36% to 8.31%)		0.83
(0.68 to 1.01)		0.069
 Fatal bleeding0.16%
(0.07% to 0.39%)		0.13%
(0.05% to 0.35%)		1.25
(0.34 to 4.67)		0.74
 Intra-articular or intramuscular with compartment syndrome0%0%N/AN/A
 Intraocular bleeding0%0.07%
(0.02% to 0.26%)		N/AN/A
 Pericardial bleeding0%0.03%
(0% to 0.23%)		N/AN/A
 Retroperitoneal bleeding0%0%N/AN/A
 Bleeding necessitating transfusion4.24%
(3.57% to 5.05%)		4.75%
(4.03% to 5.60%)		0.89
(0.70 to 1.13)		0.35
 Gastrointestinal bleeding with drop in haemoglobin ≥20 g/L1.92%
(1.49% to 2.49%)		2.19%
(1.72% to 2.78%)		0.88
(0.62% to 1.25%)		0.47

  • N/A, not availble.